High-Resolution Melting Molecular Signatures for Rapid Identification of Human Papillomavirus Genotypes

Ta-Hsien Lee1*, Tzong-Shoon Wu1,2*, Ching-Ping Tseng1,3,4*, Jiantai Timothy Qiu1,2,5,*

1 Graduate Institute of Biomedical Sciences, College of Medicine, Taoyuan, Taiwan, 2 Department of Biomedical Sciences, College of Medicine, Taoyuan, Taiwan, 3 Department of Medical Biotechnology and Laboratory Science, College of Medicine, Taoyuan, Taiwan, 4 Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan, 5 Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Abstract

Background: Genotyping of human papillomavirus (HPV) is crucial for patient management in a clinical setting. This study accesses the combined use of broad-range real-time PCR and high-resolution melting (HRM) analysis for rapid identification of HPV genotypes.

Methods: Genomic DNA sequences of 8 high-risk genotypes (HPV16/18/39/45/52/56/58/68) were subject to bioinformatic analysis to select for appropriate PCR amplicon. Asymmetric broad-range real-time PCR in the presence of HRM dye and two unlabeled probes specific to HPV16 and 18 was employed to generate HRM molecular signatures for HPV genotyping. The method was validated via assessment of 119 clinical HPV isolates.

Results: A DNA fragment within the L1 region was selected as the PCR amplicon ranging from 215–221 bp for different HPV genotypes. Each genotype displayed a distinct HRM molecular signature with minimal inter-assay variability. According to the HRM molecular signatures, HPV genotypes can be determined with one PCR within 3 h from the time of viral DNA isolation. In the validation assay, a 91% accuracy rate was achieved when the genotypes were in the database. Concomitantly, the HRM molecular signatures for additional 6 low-risk genotypes were established.

Conclusions: This assay provides a novel approach for HPV genotyping in a rapid and cost-effective manner.

Introduction

Human papillomavirus (HPV), a small and nonenveloped double-stranded DNA virus, is established as the key etiological factor in cervical neoplasms [1–3]. The recognition of the central role of HPV infections in the etiology of virtually all cervical cancers has dramatically changed the perspectives of diagnoses and prevention of this neoplasia [4,5]. Currently, HPV DNA testing plays a pivotal role for atypical squamous cells of undetermined significance, primary screening in conjunction with cytology for the detection of cervical cancer and cervical intraepithelial neoplasia, and follow-up in a variety of clinical settings [6–12]. Genotyping assays are also instrumental in assessing the impact of HPV vaccination on the risk of acquisition and on the distribution of individual HPV types in a population [8,9,13,14].

HPV infection can be monitored by detection of thirteen high-risk oncogenic HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) using a commercially available HPV testing method such as the Hybrid Capture 2 assay (Digene Corporation, Gaithersburg, MD), the only HPV assay approved by the US Food and Drug Administration [11,15,16]. However, information on HPV genotype is lacking in the cocktail detection method. Other detection systems that determine HPV genotype include non-amplification Southern and dot blot hybridization with type-specific probes [17], type-specific PCR [18,19], and broad-range PCR [5,20]. The disadvantage of type-specific PCR is that multiple hybridization reactions are needed to access multiple HPV genotypes in a single sample, while broad-range PCR such as MY09/11 has the drawback of a large PCR fragment with less sensitivity [21]. Under these circumstances, there is a clinical demand for developing a simple and accurate method for identification of infecting HPV genotype with high specificity and sensitivity.

Recently, a high-resolution melting (HRM) analysis method which incorporates double-stranded DNA saturating dye and specifically designed data collection and analyzing software has been developed. HRM analysis was first developed as a closed-tube technology for genotyping DNA variants and mutation
screening with advantages over the other techniques such as high-throughput, rapid and non-destructive nature [22–29]. Instead of using a labeled primer to analyze the domain in which the mutation resides, Wittwer and his coworkers developed HRM analysis using a saturation dye LCGreen I to substitute the need of labeled primer [28]. The combined use of real-time PCR and HRM for analysis of microbial DNA results in distinguishable HRM profiles and generates unique molecular fingerprints that facilitates its practical applications such as quantification of pathogen load and microbial species identification [30–32]. If required, heteroduplex formation or multiple PCR fragments can be employed to distinguish microbial species with closely similar HRM profile [30,31,36]. A modified HRM protocol incorporating unlabeled probes has also been reported for genotyping of herpes simplex virus that provides an alternative to detect and genotype low copies of viral infection [23].

In this study, we reported a novel method based on the use of HRM analysis and unlabeled probes to rapidly identify and differentiate HPV genotypes in clinical specimens. Without multiplexing, HPV genotypes can be completed with one PCR within 3 h from the time of viral DNA isolation.

Materials and Methods

Patients
All cervical samples were collected from the Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital with the approval by the Institutional Review Board (IRB 99-0112B) and with informed consent from the patients. The genomic DNAs of 140 consecutive HPV clinical specimens were obtained from the sample bank for this study. The individuals who performed the experiments do not know the genotype of these clinical specimens until completion of HRM analysis.

Materials
The QIAamp DNA mini kit was purchased from Qiagen (Hilden, Germany). The LightCycler 480 and the LightCycler 480 High Resolution Melting Master were purchased from Roche Applied Science (Mannheim, Germany). The Taq DNA polymerase was purchased from RBC Bioscience (Taipei, Taiwan). The McTaq DNA polymerase was purchased from One-Star Biotechnology (Taipei, Taiwan). The UniPOL-Long Range PCR enzyme mix containing Taq DNA polymerase and AccuPOL with 3′→5′ exonuclease activity was purchased from Ampliqon ApS (Skovlund, Denmark). The EasyChip HPV genotyping system was purchased from KingCar (Yilan, Taiwan).

Genomic DNA isolation
The QIAamp DNA mini kit was used to extract DNA from cervical specimen and the genomic DNA was eluted in 50 μl of elution buffer. The quality of the extracted DNA was checked by conventional PCR to amplify a housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to a 50 μl of reaction containing 5 μl of 10× PCR buffer (20 mM MgCl₂), 2 μl of 10 mM dNTP, 0.5 μl of McTaq DNA polymerase (5 U/μl), 2 μl of 5 μM forward primer GAPDH-F, 2 μl of 5 μM reverse primer GAPDH-R (Table 1) and 2 μl of template DNA. The PCR condition was 95°C for 5 min followed by 50 cycles of 95°C for 30 sec, 60°C for 40 sec, and 72°C for 60 sec. An additional 3 min of extension at 72°C was performed after the last PCR cycle to replenish PCR products followed by cooling at 4°C.

EasyChip genotyping
The HPV DNA testing was done routinely for patients who attended our dysplasia unit. Clinical DNA samples were subjected to EasyChip assay platform for HPV genotyping. The details of HPV blot format and typing procedure were described previously [37]. Briefly, 20 μl of the denatured amplicon was hybridized to the blot and the genotype was determined using streptavidin-alkaline phosphatase conjugate and substrate. After the blot was dried, the HPV genotypes displayed on the blot were determined using a standard visual assessment protocol.

Plasmid construction of L1 fragment from various HPV genotypes
Partial HPV L1 region was amplified by PCR using the clinical DNA samples of HPV16, 18, 39, 45, 52, 56, 58 and 68 and the primer pair FRG5/FRG2 (Table 1). Briefly, the PCR reaction (50 μl) was composed of 5 μl of 10× UniPOL buffer B (15 mM MgCl₂), 1 μl of 25 mM MgCl₂, 2 μl of 10 mM dNTP, 0.5 μl of the UniPOL-Long Range PCR Enzyme mix (5 U/μl), 2 μl of forward primer FRG5 (5 μM), 2 μl of reverse primer FRG2 (5 μM) and 2 μl of template DNA. The PCR condition was 95°C for 5 min followed by 50 cycles of 95°C for 30 sec, 46°C for 40 sec, and 72°C for 30 sec. An additional 3 min of extension at 72°C was performed after the last PCR cycle to replenish PCR product followed by cooling at 4°C. The PCR product was then cloned into the T&A cloning vector as described by the manufacturer’s instruction (RBC Bioscience) and was confirmed by DNA sequencing.

Symmetric and asymmetric broad-range real-time PCR and HRM analysis
For symmetric amplification of the HPV genomic DNA, broad-range real-time PCR was performed in a 384-well format using LightCycler 480. Briefly, the PCR reaction (20 μl) was composed of 10 μl of 2× HRM master mix, 2 μl of 25 mM MgCl₂, 0.8 μl of 5 μM forward primer FRG3, 0.8 μl of 5 μM reverse primer FRG2, and 2 μl of template DNA. The amplification condition was optimized for the use of FastStart Taq DNA polymerase by incubating the reaction mixtures at 95°C for 15 min, followed by 50 cycles of 95°C for 15 sec, 46°C for 20 sec, and 72°C for 30 sec with the ramp to 95°C at 4.8°C/s, to 46°C at 2.5°C/s, and to 72°C at 4.8°C/s. An additional 1 min at 72°C was added to replenish the PCR product.

For asymmetric amplification of HPV genomic DNA, the PCR reaction (20 μl) was composed of 10 μl of 2× HRM master mix, 2 μl of 25 mM MgCl₂, 0.4 μl of 2.5 μM forward primer FRG5, 2 μl of 5 μM reverse primer FRG2, 2 μl of 5 μM unlabeled probe for HPV16 and HPV18 when indicated, and 2 μl of template DNA. The unlabeled probe was modified by C6-amine or inverted dT at the 3′-end to prevent the probe from self-extension. The amplification condition was optimized for the use of FastStart Taq DNA polymerase by incubating the reaction mixtures at 95°C for 15 min, followed by 65 cycles of 95°C for 15 sec, 46°C for 20 sec, and 72°C for 30 sec with the ramp to 95°C at 4.8°C/s, to 46°C at 2.5°C/s, and to 72°C at 4.8°C/s. An additional 1 min at 72°C was added to replenish PCR product.

For HRM analysis, the PCR product was denatured by rising temperature to 95°C at 4.8°C/s and was then cool down to 55°C at 2.5°C/s for hybridization. The melting curve was acquired by increasing the temperature from 55°C to 95°C at a ramp rate of 4.8°C/s with 25 acquisitions per degree of temperature.
**Table 1.** The primers and unlabeled probes sequences.

| Primer/probe type | Primer/probe name | Sequences |
|-------------------|-------------------|-----------|
| Forward primer    | FRG5              | 5'-CARTATTATAAARCCCATATGGITACA-3' |
| Reverse primer    | FRG2              | 5'-TGAAAWATAAYTGAAACTATATCTCCTC-3' |
| Forward primer    | GAPDH-F2          | 5'-CCCTGGACCCTTACAGTCCAGCA-3' |
| Reverse primer    | GAPDH-R5          | 5'-CGTTTCTACGGTACAGGATCCAC-3' |
| Unlabeled probe   | HPV-16-UP         | 5'-ATTATTGCTGGCATATTACCTCAGA-3' |
| Unlabeled probe   | HPV-18-UP         | 5'-TGCTTCTACAGTCTTCTGACGGGCA-3' |

![Figure 1. Sequence alignments of the L1 fragment PCR amplicons.](image)

*Sequence alignments of the PCR amplicons corresponding to nt 6895 to 7115 of the L1 fragment (accession number NC_001526.1) for the indicated HPV genotypes. Only the sequences showing differences from the first sequence are shown. Nucleotides identical to the nucleotide in the first sequence are indicated by dots. The underlined sequences were used for the design of primers FRG5 and FRG2.*

doi:10.1371/journal.pone.0042051.g001
Results

To assess the combined use of real-time PCR and HRM analysis for rapid detection and differentiation of HPV genotypes, genomic DNA sequences for 8 high-risk HPV genotypes (HPV16, 18, 39, 45, 52, 56, 58 and 68) were subject to bioinformatic analysis. These genotypes represent 98% and 75% of the clinical isolates in Southeast Asia and Europe/US, respectively [37,38].

After multiple-sequence alignment of HPV genomic DNA sequences from different genotypes using the Vector NTI and BioEdit software packages, the fragments that are highly degenerated and flanked by conserved DNA sequences were chosen as the candidate targets for design of broad-range PCR to amplify HPV genomic DNA. Accordingly, a L1 fragment corresponding to nt 6895 to nt 7115 of HPV16 (accession number NC_001526.1) with the size ranging from 215 to 221 bp for different HPV genotypes was found to fulfill our selection criteria (Fig. 1). Due to the conserved nature of these nucleotides among various HPV genotypes, the nt 6895 to 6923 and nt 7087 to 7115 were selected to design the forward primer FRG5 and reverse primer FRG2, respectively (Table 1).

We determined whether asymmetric PCR of the L1 fragment followed by HRM analysis provides distinguishable melting profiles for HPV genotyping. To facilitate the assay, the PCR products corresponding to L1 fragment of various HPV genotypes were subcloned into the T&A cloning vector. These plasmids were used as the template for PCR amplification using the primers FRG5 and FRG2. Despite that most of the HPV genotypes displayed unique HRM profiles, the melting profiles for some HPV genotypes were not distinguishable. For example, HPV18 and HPV45 exhibited almost identical derivative plots and the genotypes were not likely to be determined accordingly (Fig. 2A).

To overcome this problem, we determined whether appropriate use of type-specific unlabeled probe(s) generates HRM profiles sufficient for differentiating HPV genotypes. To facilitate the

Figure 2. Asymmetric broad-range real-time PCR of L1 PCR amplicon. A and B. The L1 fragments of HPV18 and HPV45 were subject to symmetric (panel A) or asymmetric (panel B) PCR amplification using the primers FRG5 and FRG2. An unlabeled probe complementary to HPV18 target sequence was included in the reaction during asymmetric PCR. HRM analysis was then performed and the derivative plots for the indicated genotypes were shown. C-F. Serial dilution of the plasmid (from 1 pg to 10 ag) harboring the L1 fragment of HPV18 were used as the templates for asymmetric broad-range real-time PCR with the primer pair FRG5 and FRG2. (C) A typical LightCycler 480 amplification plot. (D) The $C_T$ plotted against the plasmid DNA concentration. (E) A typical high-resolution melting plot. (F) A typical high-resolution derivative plots. NTC, no-template control. doi:10.1371/journal.pone.0042051.g002
binding of unlabeled probe to the PCR product, asymmetric PCR was performed to selectively amplify the DNA strain complementary to the unlabeled probe. An unlabeled probe specific to HPV18 was designed (Table 1) and was added into the asymmetric PCR reaction. As illustrated in Fig. 2B, the HPV18-specific unlabeled probe resulted in an additional melting peak for HPV18 and thereby the genotypes of HPV18 and HPV45 can be specifically identified.

An unlabeled probe specific to HPV16 was also performed to selectively amplify the DNA strain complementary to the unlabeled probe. An unlabeled probe specific for HPV16 and HPV18 was added into the asymmetric PCR reaction. As illustrated in Fig. 2B, the HPV18-specific unlabeled probe resulted in an additional melting peak for HPV18 and thereby the genotypes of HPV18 and HPV45 can be unambiguously differentiated.

The melting temperatures and melting profiles provide molecular signatures for the 8 high-risk genotypes that can be unambiguously identified through high-resolution derivative plots (Table 2 and Fig. 3A). When clinical samples with the indicated genotypes were subject to the analyses, the melting patterns were in accord with those obtained from plasmid DNA template (Fig. 3B). Agarose gel electrophoresis further confirmed the generation of genotype-specific PCR products (Fig. 3C). The distinct HRM molecular signatures thereby provide a basis for genotyping of HPV subtypes.

The detection limit of this method was evaluated by asymmetric PCR amplification of 10-fold serially diluted plasmid DNA (from 1 pg to 10 ag) that contained 221-bp of HPV18 L1 fragment. The amplification reaction was performed in the presence of 40 ng of human genomic DNA to mimic the co-presence of HPV and human genomic DNA in clinical specimens. As revealed by amplification plots, as little as 10 ag plasmid DNA equivalent to 3 copies of HPV DNA was detectable in this assay condition (Fig. 2C). The standard curve showed a dynamic linear range for quantification across 6 logs of DNA concentrations and had a correlation coefficient of 0.9986 (Fig. 2D). Notably, both the melting and derivative plots were consistent when the amounts of template DNA from 1 pg to 10 ag were subject to asymmetric PCR amplification (Fig. 2E and 2F).

It is known that the last 6–7 nucleotides of PCR primers are critical for amplification specificity and efficiency [39,40]. Due to the degenerative nature of the FRG5 and FRG2 primers and the HPV68 genomic DNA carrying 2 mismatches at the last 7 nucleotides of the FRG5 primer region, we determined whether the efficiency for amplification of HPV68 DNA is affected. When the amounts of template DNA ranging from 1 pg to 100 ag were used, PCR amplification of HPV68 DNA was as efficient as for HPV18 DNA with no potential skewing. The presence of human genomic DNA also had no effect on amplification of HPV18 and HPV68 DNA (Fig. S1). However, 10 ag of plasmid template DNA for HPV18 but not HPV68 could be detected by this method, indicating a decrease in amplification efficiency that either due to skewing effect or a negative impact of human genomic DNA on amplifying low amount of HPV68 DNA.

The HRM profiles for 8 high-risk HPV genotypes were then generated by asymmetric broad-range real-time PCR in the presence of the unlabeled probes specific for HPV16 and HPV18. The melting temperatures and melting profiles provide molecular signatures for the 8 high-risk genotypes that can be unambiguously identified through high-resolution derivative plots (Table 2 and Fig. 3A). When clinical samples with the indicated genotypes were subject to the analyses, the melting patterns were in accord with those obtained from plasmid DNA template (Fig. 3B). Agarose gel electrophoresis further confirmed the generation of genotype-specific PCR products (Fig. 3C). The distinct HRM molecular signatures thereby provide a basis for genotyping of HPV subtypes.

We further assessed our method in HPV genotyping of clinical specimens retrospectively. A total of 140 clinical samples from patients who were suspected of having precancerous lesion were blind tested. Due to the nature of sample storage, only 119 of the 140 DNA samples were informative and generated PCR products that were suited for HRM analysis (Table 3). As revealed by EasyChip genotyping and DNA sequencing, 70 of the 119 informative cases were infected with high-risk HPV subtypes, while 49 were infected with low-risk subtypes. In addition, 65 of the 70 samples were infected with the HPV subtypes that were the analytical subjects of this study. Of the 65 samples, 59 displayed distinguishable HRM patterns that can be assigned to the correct genotype with the typing rate equivalent to 91%. According to EasyChip genotyping analysis, the remaining 6 samples were infected with multiple HPV genotypes and can not be genotyped accurately by HRM analysis (Table S1).

During our analysis of clinical specimens, several low-risk HPV genotypes including HPV42, 62, 70, CP8304, CP8061 and MM8 were found to display their unique high-resolution derivative plots (Fig. 4A and 4B). Of the 49 specimens that were infected with low-risk genotypes, 32 of them belonged to HPV42, 62, 70, CP8304, CP8061 and MM8 with 29 of them being genotyped accurately. The correct genotyping rate reached 91% (Table 3). Furthermore, 2 cases of HPV11 and 2 cases of HPV81 that were assigned as “others” (Table 3) in the low-risk group were, at the beginning, mistakenly classified as HPV54 and CP8304, respectively. All the rest of the samples (n = 18) assigned in the “others” group for both high-risk and low-risk genotypes was not falsely claimed as infected with the HPV subtypes of interest. Together, an HRM database for a total of 14 HPV genotypes was established that form the basis for HPV genotyping.

### Table 2. High-resolution melting profiles for high risk HPV genotypes disclosed by broad-range real-time PCR.

| HPV genotype (n)* | Tm ± SD (°C) | GC content (%) | GenBank accession no. |
|------------------|--------------|---------------|---------------------|
| HPV16 (5)       | 65.09±0.49   | 34            | NC001526.1          |
| HPV18 (5)       | 72.45±0.26   | 36            | KY262282.1          |
| HPV39 (5)       | 78.26±0.20   | 36            | M62849.1            |
| HPV45 (5)       | 79.81±0.17   | 36            | X74479.1            |
| HPV52 (5)       | 76.70±0.27   | 36            | EU77211.1           |
| HPV56 (4)       | 77.07±0.03   | 33            | EF177176.1          |
| HPV58 (5)       | 73.87±0.28   | 34            | D90400.1            |
| HPV68 (5)       | 72.96±0.22   | 36            | DQ800079.1          |

*Number of test (strain).

**The variance between 4–6 measurements with the indicated number of isolates.**

[doi:10.1371/journal.pone.0042051.t002]
Discussion

HPV is well recognized as a major cause of cervical cancer. The development of high grade pre-cancer and invasive cervical cancer could be due to persistent high-risk HPV infection. A rapid, accurate and sensitive method to detect and differentiate HPV genotypes is essential to identify high risk patients who are otherwise found to have normal cytological results and women with cervical cancer potential from the screened population. HPV genotyping provides a reference point for HPV vaccination and HPV prevalence in natural history studies during clinical practice. Unlike hepatitis B vaccine, there is no acceptable antibody test for HPV vaccines. If it is affordable, HPV genotyping assay should be the first choice for HPV testing. In this study, a novel approach for HPV genotyping is developed. This method is based on the combined use of asymmetric broad-range real-time PCR and HRM analysis. Accordingly, 8 high-risk and 6 low-risk HPV subtypes can be identified that offers a novel approach for HPV genotyping.

A number of HPV DNA genotyping methods including real-time multiplex PCR, Hybrid Capture II INNO-LiPA v2 HPV genotyping PCR, Roche Amplicor MWP HPV test and Digene HC2 assay have been reported in the literature [16,41–45]. Recent trends in the application of HRM analysis for microorganism identification [30,31,35] lead us to explore a new avenue to identify and differentiate HPV genotypes. Through bioinformatic analysis, we revealed that the 153–163 bp interprimer regions of FRG5 and FRG2 is relatively conserved within isolates of the same genotype, whereas nucleotide divergence is present among different HPV genotypes. Therefore, the PCR amplicon likely contains information for at least partial phylogenetic characterization for HPV genotyping. We demonstrated that 8 high-risk and 6 low-risk HPV genotypes can be identified through the HRM molecular signatures that were generated by asymmetric broad-range real-time PCR of the L1 DNA fragment in the presence of two HPV16- and HPV18-specific unlabeled probes. The relatively small PCR amplicon also results in an increase in the detection limit of this method when compared with the previously reported broad-range PCR such as MY09/11 that has a drawback of a large PCR fragment with less sensitivity [21]. Our data indicate that as little as 10 ag of plasmid DNA carrying the HPV18 PCR amplicon equivalent to 3 copies of HPV genome is detectable by this method. Due to the 2 mismatches of the last 7 nucleotides in the FRG5 primer region, the detection limit for HPV68 is slightly affected with 30 copies of genome being detected. As judged by the Ct value obtained from the analysis of clinical specimens, most of the samples contained more than 300 copies of HPV DNA. Hence, this assay should have sufficient sensitivity for most of the clinical HPV genotyping analysis. When it is combined with rapid-cycle PCR, HRM analysis requires

Table 3. The validation assay for 119 clinical HPV isolates.

| HPV type | Genotype | No. of isolates tested | No. of isolates assigned with correct genotype | Correct genotyping rate (%) |
|----------|----------|------------------------|---------------------------------------------|-----------------------------|
| High-risk | HPV16    | 15                     | 15                                          | 100                         |
|          | HPV18    | 2                      | 2                                           | 100                         |
|          | HPV39    | 11                     | 10                                          | 91                          |
|          | HPV45    | 5                      | 5                                           | 100                         |
|          | HPV52    | 8                      | 7                                           | 88                          |
|          | HPV56    | 3                      | 2                                           | 67                          |
|          | HPV58    | 14                     | 12                                          | 86                          |
|          | HPV68    | 7                      | 6                                           | 86                          |
|          | Total    | 65                     | 59                                          | 91                          |
| Othersa  |          | 5                      | -                                           | -                           |
| Low-risk | HPV42    | 7                      | 6                                           | 86                          |
|          | HPV62    | 7                      | 7                                           | 100                         |
|          | HPV70    | 6                      | 5                                           | 83                          |
|          | CP8304   | 6                      | 6                                           | 100                         |
|          | CP8061   | 2                      | 2                                           | 100                         |
|          | MM8      | 4                      | 3                                           | 75                          |
|          | Total    | 32                     | 29                                          | 91                          |
| Othersb  |          | 17                     | -                                           | -                           |

aHigh-risk HPV genotypes that are not characterized in this study.

bLow-risk HPV genotypes that are not characterized in this study.

doi:10.1371/journal.pone.0042051.t003

Figure 3. High-resolution derivative plots for 8 common and high-risk HPV genotypes. A. The plasmids carrying genotype-specific DNA fragment were subject to asymmetric broad-range real-time PCR followed by HRM analysis. The derivative plots for all 8 genotypes were plotted together to reveal the differences among different HPV genotypes. B. Two clinical samples (red and blue curves) for each indicated genotype were subject to asymmetric broad-range real-time PCR and HRM analysis. Derivative plots for the indicated HPV genotypes were plotted together with the derivative plot obtained from plasmid DNA (black curve) to reveal the consistent melting patterns between these two different sources of template DNA. C. Agarose gel electrophoresis was performed to demonstrate the generation of genotype-specific PCR products from asymmetric broad-range real-time PCR.

doi:10.1371/journal.pone.0042051.g003
minimal time, and the material cost is usually less than $3. The
time required for the differentiation of HPV genotypes is
considerably short when PCR is performed directly with clinical
specimens. Approximate 3 h is required for genotyping of the
clinical samples with the isolated DNA as the starting material.

Figure 4. Unique high-resolution derivative plots for 6 low-risk HPV genotypes. Clinical isolates that did not have derivative plots typical of
those in our HRM database were analyzed. The HPV42, 62, 70, CP8304, CP8061 and MM8 genotypes were found to display their unique high-
resolution derivative plots. The derivative plots were plotted together to reveal the differences among different HPV genotypes (panel A). The
derivative plots for two to three measurements of each HPV genotypes were plotted to reveal the minimal inter-assay variability (panel B). Note the
consistent derivative plot pattern for each virus subtype.
doi:10.1371/journal.pone.0042051.g004
Multi-infection of HPV strains with various genotypes accounts for approximate 8–22% of the HPV-infected patients [46–49]. The prevalence of multiple HPV infections varies in relation to the method used to detect HPV DNA and the study population. In addition, a potential skewing for amplification of HPV DNA in specimens containing multiple HPV genotypes by PCR with broad-range primers has been reported [49]. A technical limitation of the current method is the incapability to clearly identify the genotypes in these scenarios. Hence, among the clinical samples we analyzed in this study, the HPV genotypes for 7 HPV-positive samples that are infected with multiple HPV genotypes can not be identified by HRM analysis. However, the distinguished HRM patterns provide a hint that multiple infections may occur that required further identification with other methods.

In conclusion, the molecular signatures from HRM analysis of the broad-range real-time PCR products are useful for detection and genotyping of HPV infection. This approach can be extended further to cover all the 13 high-risk HPV genotypes. With an appropriate HRM molecular signatures database, this method should allow rapid and cost-effective differentiation of HPV genotypes.

Supporting Information

Figure S1 Effects of human genomic DNA on the amplification of HPV DNA. A–C. Serial dilution of the plasmid harboring the L1 fragment of HPV18 (panel A and C) or HPV68 (panel B and C) corresponding to the indicated copy number of template DNA were subject to amplification by asymmetric broad-range real-time PCR in the presence or absence of 20 ng of human genomic DNA. The copy numbers of the template DNA were plotted against Ct values.

(DOC)

Table S1 The genotypes for the samples with multiple infection.

(DOC)

Acknowledgments

We would like to thank Drs. Chyong-Huey Lai and Chung-Ming Chang for their support and helpful discussion in this study.

Author Contributions

Conceived and designed the experiments: THL CPT JTQ. Performed the experiments: THL. Analyzed the data: THL TSW CPT JTQ. Contributed reagents/materials/analysis tools: TSW CPT JTQ. Wrote the paper: THL TSW CPT JTQ.

References

1. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, et al. (1993) Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: 958–964.

2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12–19.

3. zur Hausen H (1996) Papillomavirus infections—a major cause of human cancers. Biochim Biophys Acta 1280: F55–78.

4. Chua KL, Hjerpe A (1996) Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 77: 121–127.

5. Hildesheim A, Schiffman MH, gravitt PE, Glass AG, Greer CE, et al. (1994) Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 169: 235–240.

6. Chao A, Lin CT, Hsueh S, Chou HH, Chang TG, et al. (2004) Usefulness of human papillomavirus testing in the follow-up patients with high-grade cervical intraepithelial neoplasia after conization. Am J Obstet Gynecol 190: 1046–1051.

7. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NB, et al. (2002) Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. Jama 288: 1749–1757.

8. Kulasingam SL, Paqulsi S, Myers E. (2007) Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine 25: 8110–8113.

9. Lai CH, Huang HJ, Hsueh S, Chao A, Lin CT, et al. (2007) Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer 120: 1999–2006.

10. Lin P, Kesony LA, Critchlow CW, Apple RJ, Haws SE, et al. (2001) HLA class II DR-DQ and risk of cervical cancer among Senegalese women. Cancer Epidemiol Biomarkers Prev 10: 1037–1045.

11. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, et al. (1999) Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. Jama 281: 1605–1610.

12. Raj GV, Moreno JG, Gomella LG (1998) Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer 82: 1419–1442.

13. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, et al. (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119: 1095–1101.

14. Franco EL, Ferenczy A (2006) Is HPV testing with cytologic triage a more logical approach in cervical cancer screening? Lancet Oncol 7: 527–529.

15. Cope JU, Hildesheim A, Schiffman MH, Manos MM, Lorincz AT, et al. (1997) Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. J Clin Microbiol 33: 2262–2265.

16. Elner T, Genn L, Swoyer R, Kjaer SK, Breugelmans JG, et al. (2009) Study comparing human papillomavirus (HPV) real-time multiplex PCR and Hybrid Capture II INNO-LiPA v2 HPV genotyping PCR assays. J Clin Microbiol 47: 2106–2113.

17. Low SH, Thong TW, Ho TH, Lee YS, Morita T, et al. (1990) Prevalence of human papillomavirus types 16 and 18 in cervical carcinomas: a study by dot and Southern blot hybridization and the polymerase chain reaction. Jpn J Cancer Res 81: 1118–1125.

18. Baay MF, Quint WG, Koudstaal J, Hollema H, Dok JM, et al. (1996) Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in parafin-embedded cervical carcinomas. J Clin Microbiol 34: 745–747.

19. Jacobs MV, Snijders PJ, Voorhees RJ, Dillner J, Fordlund O, et al. (1999) Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intra method comparison. J Clin Pathol 52: 498–503.

20. de Roda Husman AM, Snijders PJ, Stol HV, van den Brule AJ, Meijer CJ, et al. (1995) Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 72: 412–417.

21. Depuydt CE, Boulet GA, Vorath CA, Benos BY, Vereecken AJ, et al. (2007) Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med 11: 881–891.

22. Dames S, Magerl RL, Pattison DC, Wittwer CT, Voelkerding KV (2007) Characterization of aberrant melting peaks in unlabeled probe assays. J Mol Diagn 9: 290–296.

23. Dames S, Pattison DC, Bromley AK, Wittwer CT, Voelkerding KV (2007) Unlabeled probes for the detection and typing of herpes simplex virus. Clin Chem 53: 1847–1854.

24. Gundry CN, Vandersteen JG, Reed GH, Pryor RJ, Chen J, et al. (2003) Amplicon melting analysis with labeled primers: a closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem 49: 396–406.

25. Herrmann MG, Durschi JD, Bromley AK, Wittwer CT, Voelkerding KV (2006) Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clin Chem 52: 494–505.

26. Herrmann MG, Durschi JD, Wittwer CT, Voelkerding KV (2007) Expanded instrument comparison of amplicon DNA melting analysis for mutation scanning and genotyping. Clin Chem 53: 1544–1548.

27. Seipp MT, Durschi JD, Liew MA, Williams J, Djamandjio K, et al. (2007) Unlabeled oligonucleotides as internal temperature controls for genotyping by amplicon melting. J Mol Diagn 9: 284–289.

28. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ (2003) High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 49: 853–860.

29. Zhou L, Myers AN, Vandersteen JG, Wang L, Wittwer CT (2004) Closed-tube melting with unlabeled oligonucleotide probes and a saturating DNA dye. Clin Chem 50: 1328–1333.

30. Cheng JC, Huang CL, Lin CC, Chen CC, Chang YC, et al. (2006) Rapid detection and identification of clinically important bacteria by high-resolution melting analysis after broad-range ribosomal RNA real-time PCR. Clin Chem 52: 1997–2004.
31. Lin JH, Tseng CP, Chen YJ, Lin CY, Chang SS, et al. (2008) Rapid differentiation of influenza A virus subtypes and genetic screening for virus variants by high-resolution melting analysis. J Clin Microbiol 46: 1090–1097.
32. Stephens AJ, Inman-Bamber J, Giffard PM, Huygens F (2008) High-resolution melting analysis of the spa repeat region of Staphylococcus aureus. Clin Chem 54: 432–436.
33. Tajiri-Utagawa E, Haru M, Takahashi K, Watanabe M, Wakiita T (2009) Development of a rapid high-throughput method for high-resolution melting analysis for routine detection and genotyping of noroviruses. J Clin Microbiol 47: 435–440.
34. Won H, Rothman R, Ramachandran P, Hsieh YH, Keeoevic A, et al. (2010) Rapid identification of bacterial pathogens in positive blood culture bottles by use of a broad-based PCR assay coupled with high-resolution melt analysis. J Clin Microbiol 48: 3410–3413.
35. Chang SS, Hsu HL, Cheng JC, Tseng CP (2011) An efficient strategy for broad-range detection of low abundance bacteria without DNA decontamination of PCR reagents. PLoS One 6: e20303.
36. Yang S, Ramachandran P, Rothman R, Hsieh YH, Hardick A, et al. (2009) Rapid identification of biothreat and other clinically relevant bacterial species by use of universal PCR coupled with high-resolution melting analysis. J Clin Microbiol 47: 2252–2255.
37. Huang HJ, Huang SI, Lin CY, Lin RW, Chao FY, et al. (2004) Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int J Gynecol Cancer 14: 639–649.
38. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–527.
39. Kwok S, Kellogg DE, McKinney N, Spasic D, Goda I, et al. (1990) Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 18: 999–1005.
40. Huang MM, Arnhimn N, Goodman MF (1992) Extension of base mispairs by Taq DNA polymerase: implications for single nucleotide discrimination in PCR. Nucleic Acids Res 20: 4567–4573.
41. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM (1998) Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 36: 3020–3027.
42. Sandri MT, Lenzati P, Benini E, Dell'Orto P, Zorzino L, et al. (2006) Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol 44: 2141–2146.
43. van Haur MA, Bakker JM, Harbers GJ, Quint WG, Massuger LF, et al. (2005) Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol 43: 2662–2667.
44. Tucker RA, Unger ER, Holloway BP, Swan DC (2001) Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16, and 18. Mol Diagn 6: 39–47.
45. Schmitz M, Scheungraber G, Herrmann J, Teller K, Gajda M, et al. (2009) Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types. J Clin Virol 44: 302–307.
46. Coutlee F, Rainam S, Ramanakumar AV, Insaing RR, Bentley J, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 83: 1034–1041.
47. Sjoeborg KD, Trope A, Lin AK, Jonassen CM, Steinbakk M, et al. (2010) HPV geno type distribution according to severity of cervical neoplasia. Gynecol Oncol 118: 29–34.
48. Trottier H, Mahmud S, Costa MG, Sohrabho JP, Duarte-Franco E, et al. (2006) Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 15: 1274–1280.
49. Mori S, Nakao S, Kukimoto I, Kusamato-Matsuo R, Kondo K, et al. (2011) Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci 102: 1223–1227.